 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration FDA has awarded Rare Pediatric Disease Designation RPDD to Kazias paxalisib formerly GDC-0084 for the treatment of Diffuse Intrinsic Pontine Glioma DIPG, a rare and highly-aggressive childhood brain cancer. 